MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
16.57
-0.08
-0.45%
After Hours: 16.57 0 0.00% 16:02 12/01 EST
OPEN
16.70
PREV CLOSE
16.65
HIGH
16.77
LOW
16.25
VOLUME
1.22M
TURNOVER
0
52 WEEK HIGH
29.86
52 WEEK LOW
11.22
MARKET CAP
1.15B
P/E (TTM)
-6.4096
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SNDX last week (1120-1124)?
Weekly Report · 5d ago
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Syndax pharmaceuticals' estimated fair value is us$28.07 based on 2 stage free cash flow to equity. Current share price of us$15.27 suggests the company is potentially 46% undervalued. Analyst price target for sndx is 25% above its fair value.
Simply Wall St · 11/20 10:22
Weekly Report: what happened at SNDX last week (1113-1117)?
Weekly Report · 11/20 09:02
Weekly Report: what happened at SNDX last week (1106-1110)?
Weekly Report · 11/13 09:02
12 Health Care Stocks Moving In Thursday's After-Market Session
Tcon pharma stock increased by 71.3% to $0.27 during thursday's after-market session. Avita medical shares rose 20.95% after the company's, q3 earnings came out today. Treace medical concepts stock decreased by 24.1% during the session.
Benzinga · 11/09 21:31
Weekly Report: what happened at SNDX last week (1030-1103)?
Weekly Report · 11/06 09:02
Promising Clinical Trials and Strong Financial Health Drive Buy Rating for Syndax Pharmaceuticals
TipRanks · 11/06 06:23
Promising Pipeline Developments and Upcoming Approvals Bolster Buy Rating for Syndax Pharmaceuticals
Analyst justin zelin of btig has reiterated a buy rating on syndax pharmaceuticals (sndx) with a price target of $35.00. sndx's recent earnings update highlighted significant advancements in their pipeline. zelin expects two approvals for axatilimab and revumenib by next year.
TipRanks · 11/06 00:15
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 (revumenib) and SNDX-6352 (axatilimab). It is focused on developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged (MLLr), acute leukemias including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and nucleophosmin 1 (NPM1) mutant AML. Its axatilimab, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis (IPF). Its products candidate also includes entinostat, an oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.